Buy HERCEPTIN 440 MG TRASTUZUMAB

Herceptin 440 mg is a powder for solution used in intravenous therapy. It contains trastuzumab, a monoclonal antibody for targeted treatment in oncology. This medication is commonly used in cancer therapy.

Strength

440 MG

Pack Size

20ML

Manufacturer / TM Owner

HOFFMANN-LA ROCHE LIMITED

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Uses / Indications

Herceptin 440 mg is primarily used in the treatment of certain types of breast cancer and stomach cancer. It works by targeting specific proteins on cancer cells, helping to slow or stop their growth. Trastuzumab is often used in combination with other cancer treatments. What is Herceptin used for? It is used for the treatment of HER2-positive breast and stomach cancers.

Side Effects

Common effects of Herceptin 440 mg may include fatigue, nausea, and fever. Some patients may experience pain at the injection site or weakness. These effects vary among individuals and are not experienced by everyone.

Precautions & Warnings

Herceptin 440 mg should be handled with care and administered by healthcare professionals. It is important to follow the prescribed dosage and administration guidelines. Patients should inform their healthcare provider about any existing medical conditions or allergies before starting treatment.

Avoid Interactions

Herceptin 440 mg may interact with other medications, including certain chemotherapy drugs. It is important to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol and other substances should be avoided unless approved by a healthcare professional.

References

Frequently Asked Questions

Herceptin is used in the treatment of HER2-positive breast and stomach cancers. It targets specific proteins on cancer cells to help slow or stop their growth.

Herceptin is administered intravenously as a powder for solution. It should be prepared and given by healthcare professionals.

Common side effects may include fatigue, nausea, fever, and pain at the injection site. These effects vary among individuals.

Herceptin may interact with other medications, including certain chemotherapy drugs. Always consult a healthcare provider before combining treatments.

Patients with certain medical conditions or allergies should avoid Herceptin. Always inform your healthcare provider about your medical history before starting treatment.

Published by GNH India Pharmaceuticals Limited

Last updated: 18 May 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.